Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution

Clinical Cancer Research

Volumn 18, Issue 2, 2012, Pages 350-359

  Sylvester, Brooke E ^a   Huo, Dezheng ^a   Khramtsov, Andrey ^a   Zhang, Jing ^a   Smalling, Rana V ^a   Olugbile, Sope ^a   Polite, Blase N ^a   Olopade, Olufunmilayo I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

AFRICAN AMERICAN; AGED; ARTICLE; BAT25 GENE; BAT26 GENE; BAT40 GENE; BAX GENE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CAUCASIAN; CLINICAL FEATURE; CODON; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; D5S346 GENE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MOLECULAR PATHOLOGY; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84862908001     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1397     Document Type: Article

References (48)

1. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999-2005 incidence and mortality web-based report, 2009, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Cancer Institute: Atlanta. http://apps.nccd.cdc.gov/uscs/.
2. Polite B, Dignam J, Olopade O. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol 2006;24:2179-87. (Pubitemid 46630690)
3. Polite B, Dignam J, OIopade O. Colorectal cancer and race: understanding the differences in outcomes between African Americans and Whites. Med Clin N Am 2005;89:771-93. (Pubitemid 40755543)
4. Carethers J. Racial and ethnic factors in the genetic pathogenesis of colorectal cancer. J Assoc Acad Minor Phys 1999;10:59-67.
5. Troisi R, Freedman A, Devesa S. Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975-1994. Cancer 1999;85:1670-6. (Pubitemid 29169666)
6. Alexander D, Chatla C, Funkhouser E, Meleth S, Grizzle W, Manne U. Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. Cancer 2004;101:66-76. (Pubitemid 38812424)
7. Alexander D, Jhala N, Chatla C, Steinhauer J, Funkhouser E, Coffey C, et al. High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas. Cancer 2005;103:2163-70. (Pubitemid 40605125)
8. Rim S, Seeff L, Ahmed F, King J, Coughlin S. Colorectal cancer incidence in the United States, 1999-2004. Cancer 2009;115:1967-76.
9. Fairley T, Cardinez C, Martin J, Alley L, Friedman C, Edwards B, et al. Colorectal cancer in U.S. adults younger than 50 years of age, 1998-2001. Cancer 2006;107 (5 Suppl):1153-61. (Pubitemid 44384821)
10. Cheng X, Chen V, Steele B, Ruiz B, Fulton J, Liu L, et al. Subsite-specific incidence rate and stage of disease in colorectal cancer by race, gender, and age grouping the United States, 1992-1997. Cancer 2001;92:2547-54. (Pubitemid 33049437)
11. Markowitz S, Bertagnolli M. Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
12. Ribic C, Sargent D, Moore M, Thibodeau S, French A, Goldberg R, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57. (Pubitemid 36859476)
13. Watanabe T, Wu T, Catalano P, Ueki T, Satriano R, Haller D, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-206. (Pubitemid 32319494)
14. Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S, et al. Muations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
15. Samowitz W, Sweeney C, Herrick J, Albertsen H, Levin T, Murtaugh M, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-70. (Pubitemid 40994390)
16. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. JNCI 2009;101:1308-24.
17. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
18. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein H, Soderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-33. (Pubitemid 38528645)
19. Yuen S, Davies H, Chan T, Ho J, Bignell G, Cox C, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62:6451-5. (Pubitemid 35364105)
20. Ashktorab H, Smoot D, Farzanmehr H, Fidelia-Lambert M, Momen B, Hylind L, et al. Clincopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer 2005;116:914-9. (Pubitemid 41209198)
21. Wu C, Tang R, Wang J, Changchien C, Hsieh L. Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genet Cytogen 2005;158:55-60. (Pubitemid 40354325)
22. Brink M, de Goeij A, Weijenberg M, Roeman G, Lentjes M, Pachen M, et al. K-ras oncogenes mutations in sporadic colorectal cancer in the Netherlands Cohort Study. Carcinogenesis 2003;24:703-10. (Pubitemid 36592405)
23. Boland C, Thibodeau S, Hamilton S, Sidransky D, Eshleman J, Burt R, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57. (Pubitemid 28521189)
24. Jenkins M, Hayashi S, O'Shea A, Burgart L, Smyrk T, Shimizu D, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007;133:48-56. (Pubitemid 47039240)
25. Bos J, Fearon E, Hamilton S, Verlaan-de Vries M, van Boom J, van der Eb A, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-7. (Pubitemid 17075079)
26. Rajagopalan H, Bardelli A, Lengauer C, Kinzler K, Vogelstein B, Velculescu V. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934. (Pubitemid 34976022)
27. Vilar E, Gruber S. Microsatellite instability in colorectal cancer - the stable evidence. Nat Rev Clin Oncol 2010;7:153-62.
28. Sargent D, Marsoni S, Monges G, Thibodeau S, Labianca R, Hamilton S, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219-26.
29. Ionov Y, Peinado M, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-61. (Pubitemid 23186645)
30. Brim H, Mokarram P, naghibalhossaini F, Saberi-Firoozi M, Al-Mandhari M, Al-Mawaly K, et al. Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer 2008;7:68-78.
31. Kumar K, Brim H, Giardiello F, Smoot D, Nouraie M, Lee E, et al. Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res 2009;15:1155-61.
32. Ogino S, Nosho K, Kirkner G, Kawasaki T, Meyerhardt J, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
33. Hughes L, Simons C, van den Brandt P, Goldbohm R, de Goeij A, de Bruine A, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One 2011;6:e18571.
34. SamowitzW, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery M. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000;9:1193-7.
35. Nosho K, Irahara N, Shima K, Kure S, Kirkner G, Schernhammer E, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008;3:e3698.
36. Roth A, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
37. French A, Sargent D, Burgart L, Foster N, Kabat B, Goldberg R, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008;14:3408-15.
38. Richman S, Seymour M, Chambers P, Elliott F, Daly C, Meade A, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do no preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;35:5931-7.
39. Ogino S, Meyerhardt J, Irahara N, Niedzwiecki D, Hollis D, Saltz L, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009;15:7322-9.
40. Young F, Hu Y, Le Leu R, Nyskohus L. Dietary fibre and colorectal cancer: a model for environment-gene interactions. Mol Nutr Food Res 2005;49:571-84. (Pubitemid 40853703)
41. Johnson I. New approaches to the role of diet in the prevention of cancers of the alimentary tract. Mutation Res 2004;551:9-28. (Pubitemid 38833494)
42. Cross A, Sinha R. Meat-related mutagens/carcinogens in the etiology of colorectal cancer. Environ Mol Mutagen 2004;44:44-55. (Pubitemid 38982072)
43. Le Marchand L, Donlon T, Seifried A, Wilkens L. Red meat intake, CYP2E1 genetic polymorphisms, and colorectal cancer risk. Cancer Epidem Biomar 2002;11:1019-24. (Pubitemid 35192652)
44. Fu Z, Shrubsole M, Smalley W,WuH, Chen Z, Shyr Y, et al. Association of meat intake and meat-derived mutagen exposure with the risk of colorectal polyps by histologic type. Cancer Prev Res 2011;4:1686-97.
45. Tanaka N, Huttenhower C, Nosho K, Baba Y, Shima K, Quackenbush J, et al. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am J Pathol 2010;177:2731-40.
46. Barault L, Charon-Barra C, Jooste V, Funes de la Vega M, Martin L, Roignot P, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008;68:8541-6.
47. Samowitz W, Albertsen H, Herrick J, Levin T, Sweeney C, Murtaugh M, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-45. (Pubitemid 41242676)
48. Polite B, Sylvester B, Olopade O. Race and subset analyses in clinical trials: time to get serious about data integration. J Natl Cancer Inst 2011;103:1486-8.